<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644448</url>
  </required_header>
  <id_info>
    <org_study_id>KRPL/HPL-FR/11-12/002A</org_study_id>
    <nct_id>NCT01644448</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety &amp; Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark Circles</brief_title>
  <official_title>A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety &amp; Efficacy Of Autologous Human Platelet Lysate (HPL) for Treatment of Periorbital Hyperpigmentation (Dark Circles)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasiak Research Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasiak Research Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open label, randomized, pilot study to evalute safety and efficacy of
      Human Platelet Lysate (HPL) in subjects with Periorbital Hyperpigmentation. The study is
      being conducted at 2 centers in India.The primary endpoints are Physicians and Patient Self
      assessment score. The secondary endpoints are improvement in photographic assessment form
      randomization to end of study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photographic Assessment</measure>
    <time_frame>Day 0, Month 1, Month 2, End of Study - 3 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Physician's assessment scores</measure>
    <time_frame>End of Study - 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's assessment scores</measure>
    <time_frame>End of Study - 3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Periorbital Hyperpigmentation (Dark Circles)</condition>
  <arm_group>
    <arm_group_label>Study arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Topical Applications of the standard therapy as directed by the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Human Platelet Lysate</intervention_name>
    <description>Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2</description>
    <arm_group_label>Study arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Therapy</intervention_name>
    <description>Topical Applications as directed by the investigator</description>
    <arm_group_label>Control Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects (male and female), aged 18 to 55 years (both inclusive) with Periorbital
             Hyperpigmentation.

          -  Subject willing to refrain from any other treatment of Periorbital Hyperpigmentation
             during entire study duration.

          -  Subjects who are willing to give informed consent and adhere to the study protocol.

        Exclusion Criteria:

          -  Subjects aged less than 18 and more than 55 years

          -  Subjects with history of connective tissue disease.

          -  Subjects with metabolic or hematopoietic disorders

          -  Subjects unwilling to or unable to comply with the study protocol.

          -  Subjects taking concomitant therapy that might interfere with the study results in the
             investigator's opinion or participating in another trial in the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farida Modi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermacare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Preeti Savardekar, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shree Krishna Polyclinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharmila Patil, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Sharmila's Dermocosmetic laser center, hair and skin clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasiak Research Pvt Ltd</name>
      <address>
        <city>Thane</city>
        <state>Maharashtra</state>
        <zip>400610</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

